PERTH, Australia, 12 January 2018: Phylogica Limited (ASX:PYC) (Phylogica or the Company), developer of a leading intracellular drug delivery platform technology, is pleased to announce the appointment of Professor Shohei Koide to the Scientific Advisory Board (SAB).
Together with the recent SAB appointments of Prof. Judy Lieberman and Dr. Stephen Doberstein, Professor Koide will serve as a strategic resource for Phylogica as the Company continues to develop its intracellular drug delivery technology.
Commenting on the appointment, Dr. Rob Hayes, Phylogica’s CSO said, “We are delighted that Shohei has agreed to join our SAB. He brings deep expertise in cancer, protein design, protein engineering, biologics and drug discovery. His influence on the rational design of biologics is demonstrated in several important scientific papers and biotech companies which owe their existence to his early work.”
For further information please download PDF attached:
Download this document
